| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2347 | Gsk1104252a | Potent and selective GPR119 agonist |
|
| DCC2348 | Gsk1180781a | Novel selective inhibitor of MmpL3 mutation |
|
| DCC2349 | Gsk-1264 | Novel allosteric inhibitor of human immunodeficiency virus (HIV) integrase, blocking viral replication and abnormal multimerization involving specific protein domains |
|
| DCC2350 | (BrMT)2 | Non-peptidic snail toxin; Activator of the Kv1.1 potassium ion channel |
|
| DCC2351 | Gsk1370319a | Novel specific P2X(7) receptor antagonist |
|
| DCC2352 | Gsk1379767a | Novel dual inhibitor of BPTF and Brd4 |
|
| DCC2353 | Gsk1452496a | Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv |
|
| DCC2354 | Gsk1452498a | Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv |
|
| DCC2355 | Gsk1723980 | Novel noncompetitive inhibitor of rTbIPMK |
|
| DCC2356 | Gsk1733953a Featured | Novel Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG |
|
| DCC2357 | Gsk1829820a | Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv |
|
| DCC2358 | Gsk189254 | Potent and selective H3 histamine receptor inverse agonist |
|
| DCC2359 | Gsk1910364 | Novel inhibitor of EPHX2 (epoxide hydrolase 2, alias soluble epoxide hydrolase or sEH), up-regulating cytoprotective genes and down-regulating proinflammatory cytokine production |
|
| DCC2360 | Gsk1997132b | Novel potent, metabolically stable and centrally penetrant PPARγ partial agonist |
|
| DCC2361 | Gsk2008607 | Novel competitive inhibitor of rTbIPMK with respect to Ins(1,4,5)P3 |
|
| DCC2362 | Gsk207040 | Novel selective non-imidazole histamine H 3 receptor antagonist |
|
| DCC2363 | Gsk2141795 Hydrochloride | Novel AKT Inhibitor, Enhancing Anti-Tumor Effects in Combination with the MEK Inhibitor |
|
| DCC2364 | Gsk2163632a | Novel insulin-like growth factor 1 receptor inhibitor, binding to a novel region of the GRK active site cleft that could likely be exploited to achieve more selectivity |
|
| DCC2365 | Gsk2188764 | Novel inhibitor of T. brucei IPMK, partially inhibiting rTbIPMK activity |
|
| DCC2366 | Gsk2220400a | Inhibitor of insulin receptor, also tageting IGF-1R and ALK |
|
| DCC2367 | Gsk223 | Selective inhibitor of iE-DAP-stimulated IL-8 release via the NOD1 signaling pathway |
|
| DCC2368 | Gsk2256294a | Novel highly potent, reversible soluble epoxide hydrolase (sEH) inhibitor, exhibiting potent cell-based activity, a concentration-dependent inhibition of the conversion of 14,15-EET to 14,15-DHET, attenuating cigarette smoke-induced inflammation by both i |
|
| DCC2369 | Gsk2263167 | Novel S1P1 receptor agonist |
|
| DCC2370 | Gsk237701a | Novel I-kappa-B kinase-3 (IKK3) inhibitor |
|
| DCC2371 | Gsk-239512 | Novel selective histamine H3 receptor antagonist |
|
| DCC2372 | Gsk246053 | Specific ATPase competitive kinesin-5 inhibitor |
|
| DCC2373 | Gsk2565363c | Betulin derivative as antitumor agent |
|
| DCC2374 | Gsk270822a | Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2) |
|
| DCC2375 | Gsk-2807 | Novel potent and selective, SAM-competitive inhibitor of SMYD3 |
|
| DCC2376 | Gsk2838232 | Novel human immune virus (HIV) maturation inhibitor |
|
